. 2005 Dec 29;107(8):3091–3097. doi: 10.1182/blood-2005-10-4057

Table 2.

Gene-corrected (GFP⁺) peripheral blood cells in all 4 dogs 8 weeks following intravenous gene therapy as determined by flow cytometry

	Neutrophils			Monocytes			Lymphocytes			CD3⁺				CD21⁺
Dog no.	No.^*	% GFP⁺	No. GFP⁺^*	No.^*	% GFP⁺	No. GFP⁺^*	No.^*	% GFP⁺	No. GFP⁺^*	%	No.^*	% GFP⁺	No. GFP⁺^*	%	No.^*	% GFP⁺	No. GFP⁺^*
1551	5 420	1.0	54	340	0.6	2	560	38.7	216	49.1	274	71.1	195	28.7	160	8.4	14
1548	11 000	3.2	352	770	5.9	45	7200	52.8	3802	64.8	4665	78.5	3662	7.9	568	26.5	151
1547	5 900	1.5	88	860	4.5	39	3400	65.2	2217	69.5	2363	78.0	1843	4.9	167	6.1	10
1655	6 320	3.8	242	930	11.1	102	3850	61.0	2348	65.3	2514	84.5	2120	20.3	782	24.2	189

Normal ranges were determined in 8-week-old unaffected dogs and are as follows: neutrophils, 8500 ± 2900 cells/μL; monocytes, 1400 ± 700 cells/μL; lymphocytes, 5000 ± 1500 cells/μL; CD3⁺, 76.2% ± 14.4%; and CD21⁺, 12.9% ± 8.6%. The percentage of GFP⁺ cells in untreated control dogs (background signal) was less than 0.05%.

To convert neutrophil, monocyte, or lymphocyte counts to × 10⁹ cells/L, divide cells/μL by 1000.

Cells/μL.